Get Premium to unlock powerful stock data
Lipocine Inc logo

Lipocine Inc

$ 0.86 +0.0001 (+0.01%) 10:08 PM EST
P/E:
At Loss
P/B:
1.80
Market Cap:
$ 76.12M
Enterprise V:
$ 35.60M
Volume:
260.65K
Avg Vol (2M):
705.07K
Also Trade In:
Volume:
260.65K
Market Cap $:
76.12M
PE Ratio:
At Loss
Avg Vol (2-Month):
705.07K
Enterprise Value $:
35.60M
PB Ratio:
1.80
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Lipocine Inc
NAICS : 325412 SIC : 2834
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Description
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO, is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Name Current Vs Industry Vs History
Cash-To-Debt 28.34
Equity-to-Asset 0.89
Debt-to-Equity 0.04
Debt-to-EBITDA -2.48
Interest Coverage 20.31
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.92
Distress
Grey
Safe
Beneish M-Score 78.17
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 45.27
9-Day RSI 46.19
14-Day RSI 42.83
6-1 Month Momentum % -20.09
12-1 Month Momentum % -27.18

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.36
Quick Ratio 12.36
Cash Ratio 11.93
Days Payable 47.37

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -59.6

Financials (Next Earnings Date:2022-08-05 Est.)

LPCN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:LPCN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 16.141
EPS (TTM) ($) -0.01
Beta 0.47
Volatility % 53.42
14-Day RSI 42.83
14-Day ATR ($) 0.076203
20-Day SMA ($) 0.844205
12-1 Month Momentum % -27.18
52-Week Range ($) 0.708 - 1.89
Shares Outstanding (Mil) 88.5

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Lipocine Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More